Inactivated human rotavirus vaccine induces heterotypic antibody response: Correction and development of IgG avidity assay

Abstract

To improve lower efficacy among infants in low income countries and the safety (e.g., rare but severe intussusception) of live oral rotavirus vaccines, we have developed CDC-9 strain with G1P[8] specificity as a candidate inactivated rotavirus vaccine (IRV). This IRV of 3 doses elicits high titers of IgG, neutralizing activity to homotypic and heterotypic human strains and IgG avidity in guinea pigs, thus is a promising alternative to enhance global immunization against rotavirus in children.

Keywords:

• CDC-9
• heterotypic protection
• IRV
• IgG-avidity
• rotavirus

Disclosure of Potential Conflicts of Interest

Drs. Jiang and Glass and Ms. Wang hold patents through CDC for their work with inactivated rotavirus vaccine.

Acknowledgments

We thank W.J. Bellini and S. Mercader for assistance in developing rotavirus-specific IgG avidity assay and Stan Cryz of PATH for sponsoring the immunogenicity testing of IRV in guinea pigs. The finding and conclusions in this report are those of the authors and do not necessarily represent the official positions of Centers for Disease Control and Prevention.